

### Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application:

#### Listing of Claims:

Claim 1 (currently amended): A composition having formula I or II:



wherein:

$X_1$  is from zero to twenty natural or synthetic amino acids;

P is a peptide ~~comprising~~ having the amino acid sequence Gly-Pro-Arg Gly-Pro-Arg (SEQ ID NO: 1), or an analog or a peptide fragment thereof;

$X_2$  is from zero to twenty natural or synthetic amino acids;

Z is a linker comprising one or more natural or synthetic amino acids; and


M is a radiolabeling moiety ~~comprised of a~~ comprising a peptide chelating moiety capable of complexing with a selected radionuclide in an  $N_4$  configuration.


Claim 2 (cancelled).

Claim 3 (original): The composition according to claim 1, wherein the radiolabeling moiety is complexed to the radionuclide.

Claim 4 (original): The composition according to claim 3, wherein the radionuclide is technetium-99m.

Claim 5 (currently amended): The composition according to claim 3, having the formula:





Claim 6 (currently amended): The composition according to claim 1, wherein M comprises Gly—(D)-Ala-Gly-Gly (SEQ ID NO: 4) ~~as a chelating moiety for a radionuclide.~~

Claim 7 (original): A method of imaging mammalian cells or tissue, comprising administering a diagnostically effective amount of the composition of claim 1 to a mammal at a target site and detecting the composition at said target site.

Claim 8 (currently amended): The method of claim ~~[[6]]~~ 7, wherein said target site is a mammalian thrombus.

Claim 9 (currently amended): A method of imaging a thrombus in a mammal, comprising:  
(a) administering a diagnostically effective amount of a composition according to claim 1 that binds to fibrin, ~~said composition having a radiolabeling moiety;~~ and  
(b) detecting said composition at ~~site of~~ said thrombus.